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Abstract  
In patients with idiopathic noncirrhotic portal hypertension (INCPH), data on morbi-mortality 
of abdominal surgery are scarce We retrospectively analyzed the charts of patients with 
INCPH undergoing abdominal surgery within the VALDIG network. Forty-four patients with 
biopsy-proven INCPH were included. Twenty-five (57%) patients had ≥1 extrahepatic 
conditions related with INCPH and 16 (36%) had a history of ascites. Forty-five procedures 
were performed, including 30 minor and 15 major. Nine (20%) patients had 1 Dindo-
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portal hypertension related complication within 3 months after surgery. Extrahepatic 
conditions related with INCPH (p=0.03) and history of ascites (p=0.02) were associated with 
portal hypertension related complications within 3 months after surgery. Splenectomy was 
associated with development of portal vein thrombosis after surgery (p=0.01). Four (9%) 
patients died within 6 months after surgery. Six-month cumulative risk of death was higher in 
patients with serum creatinine 100 mol/L at surgery (33%, vs. 0%, p<0.001). An 
unfavorable outcome (i.e. either liver or surgical complication or death) occurred in 22 (50%) 
patients and was associated with presence of extra-hepatic conditions related with INCPH, 
history of ascites and serum creatinine 100 mol/L: Five percent of the patients with none 
of these features had an unfavorable outcome, vs. 32% and 64% when one or  2 features 
were present, respectively. Portal decompression procedures prior to surgery (n=10) were 
not associated with post-operative outcome. Conclusion. Patients with INCPH are at high-
risk of major surgical and portal hypertension related complications when they harbor 
extrahepatic conditions related with INCPH, history of ascites or increased serum creatinine.  
 
 Idiopathic noncirrhotic portal hypertension (INCPH) is a heterogeneous group of rare 
diseases causing portal hypertension and characterized by the absence of cirrhotic 
modification of the liver parenchyma and the patency of portal and hepatic veins. In Europe, 
INCPH accounts for less than 2% of the indications for liver biopsies (1,2). Liver histological 
lesions found in patients with INCPH include obliterative portal venopathy, hepatoportal 
sclerosis, nodular regenerative hyperplasia and incomplete septal cirrhosis (3). INCPH has 
been associated with various conditions including thrombophilia, hematologic malignancies, 
human immunodeficiency virus (HIV) infection, genetic and immunological disorders (4,5). 
Patients with INCPH may develop portal hypertension related complications, but usually 
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Patients with chronic liver diseases may require abdominal surgery for indications related to 
their liver disease (e.g. splenectomy or parietal surgery), or unrelated. Most available data 
on the risk of surgery in patients with liver disease pertains to cirrhosis, where post-operative 
morbidity and mortality are influenced by liver dysfunction and degree of portal hypertension 
(6–9), type of surgery (10,11) and comorbidities (9). Given the link between portal 
hypertension and post-operative outcome (11), portal decompression has been proposed to 
facilitate abdominal surgery and improve outcome, although reported results are contrasted 
(12–17). 
Experience regarding abdominal surgery in patients with INCPH is mostly limited to 
portosystemic shunt and/or splenectomy performed in adults or children from Eastern 
countries (5,18–20). The present study thus aimed at evaluating the outcome of patients 
with INCPH undergoing abdominal surgery and at assessing the impact of preoperative 
portal decompression procedures.  
 
Patients and Methods 
Patients 
Between April 2017 and November 2017, we contacted all the centers participating in the 
Vascular Liver Disease Interest Group (VALDIG) or the French network for vascular liver 
diseases to retrospectively identify all patients with INCPH having had ≥1 abdominal 
surgery. Surgeries were considered only if INCPH was known prior to the procedure or 
diagnosed at the time of the surgery. Patients’ identification was based on local databases. 
The study was approved by our institutional review board (CCER 2017-01219) and 
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Definitions 
Diagnosis of INCPH was based on the criteria proposed by the VALDIG group, after 
exclusion of cirrhosis (Supplementary Table 1). Histologic diagnosis of INCPH was 
confirmed by pathologists experts in liver diseases. Patients with portal vein thrombosis 
were included in this study if this thrombosis occurred after INCPH diagnosis. Patients with 
chemotherapy-induced non-cirrhotic portal hypertension, and/or who underwent liver 
resection for colorectal liver metastasis were not included, since the main liver lesion in 
these patients is sinusoidal obstruction syndrome, i.e. a distinct entity from INCPH (21).  
Date of diagnosis of INCPH was the date the first liver biopsy demonstrating the absence of 
cirrhosis while signs of portal hypertension were already present, as detailed in 
supplementary Table 1. According to the previous reports, extra-hepatic conditions 
associated with INCPH were classified into the following categories (22–25): immunological 
disorders (autoimmune conditions, common variable immune deficiency, history of solid 
organ transplantation, Crohn’s disease, human immunodeficiency virus infection), recurrent 
abdominal infections, medication or toxins, prothrombotic state (myeloproliferative 
syndrome, heterozygous factor II or V Leiden, or familial history of venous 
thromboembolism), genetic disorders.  
The following data were collected at surgery: (a) clinical features before surgery, including 
age, gender, American Society of Anesthesiology (ASA) class (26), age-adjusted Charlson 
comorbidity index (the Charlson Comorbidity index is a weighted index that takes into 
account the number and the seriousness of comorbid diseases by assigning points for 
certain illnesses (27); the age-adjusted Charlson comorbidity index assigns an additional 
point for each decade of life after 50 years of age), clinical, laboratory, imaging and 
endoscopic features; (b) surgical data, including indication, type of surgery, planned or 
emergency procedure, laparoscopy or laparotomy. Major surgery was defined as laparotomy 
with operative intervention on a visceral organ (9). History of ascites was defined as a 
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detectable ascites at surgery. Portal decompression intervention before surgery included 
TIPSS placement or surgical portosystemic shunt. Patients in whom surgical portosystemic 
shunt was the indication for surgery were not included. 
 
Follow-up 
Duration of follow-up was calculated from the date of surgery. End-points were pre-specified 
before data collection (Supplementary Table 2). Postoperative complications were defined 
as any event occurring within one month after surgical intervention, and was categorized 
according Dindo-Clavien classification. (28). Portal hypertension-related complications were 
defined as any of decompensation ascites, hepatic encephalopathy, significant portal 
hypertension related bleeding (29), acute kidney injury, or spontaneous bacterial peritonitis 
occurring within 3 months after surgical intervention (Supplementary Table 2). 
Decompensation of ascites was defined as follows: (i) in patients without ascites, onset of 
clinically detectable ascites, confirmed by ultrasonography; (ii) in patients with previous 
ascites not requiring paracentesis, ascites requiring two or more paracenteses within 3 
months following surgery, or requiring a TIPSS. Post-operative death was defined as death 
occurring within 6 months after surgical intervention. Finally, an unfavorable outcome was 
defined either post-operative grade 3 complication according to Dindo-Clavien classification 
within one month after surgery, or portal-hypertension related complications within 3 months 
after surgery, or death within 6 months after surgery.  
In order to evaluate the influence of portal decompression on post-operative outcome, we 
compared the occurrence of complications between patients who had or not a history of 
portal decompression procedure, i.e. TIPSS placement or surgical portosystemic shunt, 
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Controls  
We compared 6-month post-operative cumulative risk of death in patients with INCPH with 
that of patients with cirrhosis who had abdominal surgery, selected from a recently published 
cohort (17). Two patients with cirrhosis were matched with one patient with INCPH 
according to the presence of ascites at surgery (i.e either clinically detectable ascites before 
TIPS placement or history of ascites at the time of surgery (i.e. previous ascites controlled 
with diuretic therapy at surgery, or clinically detectable ascites at surgery).  
We also compared 3-year liver transplantation-free survival of patients with INCPH who had 
abdominal surgery, i.e. patients from the present cohort, with that of patients with INCPH 
who did not undergo abdominal surgery, prospectively included between January 2011 and 
June 2018 at the liver hemodynamic unit at Beaujon Hospital (Clichy, France). Diagnosis of 
INCPH was based on the criteria proposed by the VALDIG group, after exclusion of cirrhosis 
(Supplementary Table 1). Among the 101 patients meeting these criteria, 7 were excluded 
because they were referred to the liver hemodynamic unit for evaluation before liver 
transplantation, 9 because follow-up data were not available, and 3 because they were 
already included in the present study.  
 
Statistical analysis 
Results are presented as median (interquartile range (IQR)) or absolute number 
(percentage). Comparisons between quantitative variables were performed using the T test 
or Mann-Whitney test for normally and non-normally distributed variables, respectively. 
Shapiro–Wilk test was used to determine whether or not the distribution of continuous 
variable was normal. Comparisons between categorical variables were performed using the 
Chi-square or Fisher exact test, when appropriate. Univariate Cox regression analyses were 
performed to determine factors associated with post-operative complication grade 3 within 
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surgery, death within 6 months after surgery or unfavorable outcome after surgery. Factors 
included in the univariate analysis were pre-specified based on their previous identification 
as prognostic factors in patients with cirrhosis undergoing surgery and/or in patients with 
INCPH. These factors included age-adjusted Charlson comorbidity index (30), extrahepatic 
condition associated with INCPH (23–25), history of ascites at the time of surgery (i.e. 
previous ascites controlled with diuretic therapy at surgery, or clinically detectable ascites at 
surgery) (23–25,31), varices needing treatment (i.e. medium/large esophageal and/or gastric 
varices or history of variceal bleeding or history of endoscopic band ligation and/or glue) 
(11,31), portal vein thrombosis at surgery (22), serum bilirubin at surgery (8,9,31,32), serum 
creatinine at surgery (8,9,24,31,33), major surgery (9,10), and emergency procedures (6–
8,32). Although MELD and Child-Pugh scores are known to be associated with post-
operative outcome after abdominal surgery in patients with cirrhosis (9,32,33), we 
deliberately chose not to insert these scores, but rather serum creatinine and bilirubin, since 
6 patients were treated with vitamin K antagonists and since serum albumin concentration 
was available in only 34/44 patients. We did not analyze HVPG because HVPG is not a 
good reflection of portal hypertension in patients with INCPH (25,34).  
 
In order to assess the influence of portal decompression on postoperative outcome, we 
performed additional analyses including portal decompression in the Cox regression 
analysis. Hazard ratio (HR) for Cox logistic regression were provided with their 95% 
confidence interval (CI). Cumulative risk of death was assessed according to the Kaplan–
Meier method and compared using the log-rank test. All tests were two-sided and p ≤0.05 
was considered to be significant. Data handling and analysis were performed with SPSS 
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Results 
Patients’ characteristics at surgery 
Between 2002 and 2017, 45 surgical interventions were performed in 44 patients from 10 
centers participating in the VALDIG network or the French network for vascular liver disease 
(Supplementary Table 4). Their characteristics at the time of surgery are presented in Table 
1. INCPH was diagnosed at the time of surgery in 8 (18%) patients. In the 36 other patients, 
median time between INCPH diagnosis and surgery was 26 (6-50) months. Prevalence of 
signs of portal hypertension at INCPH diagnosis, namely ascites and gastroesophageal 
varices, was similar between the 8 patients in whom INCPH was diagnosed at surgery and 
the 36 patients with known INCPH at surgery (data not shown). At least one extra-hepatic 
condition associated with INCPH was present in 25 (57%) patients, including 23 with either 
immunological disorder or HIV infection. Fourteen (32%) had 2 or more conditions. Age-
adjusted Charlson comorbidity index was 3 in 35 (80%) patients, indicating that significant 
comorbidities were common. Liver function was preserved in the majority of the patients, 
since 32 (73%) patients had serum bilirubin ≤ 34 mol/L, 32 (73%) had INR < 1.5, none had 
hepatic encephalopathy and only 7 (16%) patients had clinically detectable ascites, including 
2 (5%) with tense ascites at surgery (Table 1). Eleven (25%) patients had serum creatinine 
≥100 µmol/L before surgery. HVPG was measured in 28 (64%) patients. Median (IQR) 
HVPG was 9 (6-15) mm Hg.  
Sixteen (36%) patients were treated with anticoagulants before surgery, including low 
molecular weight heparin (n=7), non-fractioned heparin (n=1), fondaparinux (n=1), 
rivaroxaban (n=1) and vitamin K antagonists (n=6). Among these 16 patients, 
anticoagulation was stopped before surgical intervention in 8 patients. Thus, 8 (18%) 
patients were still treated with anticoagulation therapy at the date of surgery. Seven (16%) 
patients were treated with antiplatelet agents before surgery, including aspirin (n=6) and 
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surgical intervention in 2 patients. Thus, 5 (11%) patients were still treated with antiplatelet 
agents at the date of surgery. 
Type of, and indications for abdominal surgery are detailed in Table 2. One patient 
underwent 2 different operations (emergency surgery for perforated gastric ulcer suture, 
followed by elective abdominoplasty, 2 years later). There were 15 (33%) major and 30 
(67%) minor interventions (including 12 laparoscopic surgeries). Eleven interventions (24%) 
were emergency surgeries, whereas the 34 (76%) remaining were planned interventions. 
Among the 7 patients with elevated serum creatinine concentration (i.e. serum creatinine 
≥100 µmol/L) and a history of ascites at surgery, 3 had major surgery and 2 others had 
surgery in emergency (Supplementary Table 5). In the peri-operative period, red blood cells 
and platelets were transfused in 11 (24%) and 8 (18%) patients, respectively. 
 
Post-operative complications within 1 month after surgery 
According to the Dindo-Clavien classification, 61 post-operative complications occurred in 31 
(70%) patients within 1 month after surgery (Table 3). In median, 2 (1.0-3.0) complications 
occurred per patient. In 9 (20%) patients, post-operative complications were classified as 
grade ≥3 or more according to the Dindo-Clavien classification.  
Ten (22%) patients developed post-operative bleeding, including 4 classified as grade ≥3 
according to the Dindo-Clavien classification. Three patients required an intervention 
(surgical or radiological), and 2 required transfusion of red blood cells and/or platelet units 
(Supplementary Table 6). Antiplatelet agents at surgery (3/10 (30%) vs. 2/35 (6%), p=0.03), 
as well as anticoagulation (5/10 (50%) vs. 3/35 (9%), p=0.003) were the only factors 
associated with post-operative bleeding among those tested, as indicated in Table 1. 
Platelet count at surgery was similar in patients with or without post-operative bleeding 
(p=0.6).  
Nineteen post-operative infections occurred in 15 (33%) patients, including only one 
classified as grade ≥3 according to Dindo-Clavien classification. No patient developed post-
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As shown in Table 4, none of the pre-specified factors were significantly associated with the 
development of at least one grade ≥3 complications according to the Dindo-Clavien 
classification.  
 
Portal hypertension related complications within 3 months after surgery 
Twenty-seven portal hypertension related complications occurred in 16 (36%) patients within 
3 months after surgery. Median time between surgery and occurrence of such complications 
was 6 (1-17) days. Decompensation of ascites, occurring in 12 (26%) patients, was the most 
frequent of such complications. In two patients, a TIPSS was placed for refractory ascites, 
5.9 and 7.5 months after surgery, respectively. Hepatic encephalopathy, variceal bleeding, 
spontaneous bacterial peritonitis and acute kidney injury occurred in 3 (7%), 2 (4%), 3 (7%) 
and 7 (16%) patients, respectively. One patient had TIPSS placement for refractory variceal 
bleeding 14 days after surgery. Resolution of portal hypertension related complication 
occurred in 15 out of the 16 patients, after 26 (10-59) days. One patient died 5.7 months 
after surgery (Patient 7, Table 5). Length of hospital stay was significantly longer in patients 
who developed portal hypertension related complications than in those who did not (30 (6-
45) days vs. 6 (3-16) days, p=0.002).  
Factors associated with the occurrence of at least one portal hypertension related 
complication included a history of ascites and extra-hepatic conditions associated with 
INCPH. Serum creatinine at surgery was not associated with the occurrence of at least one 
portal hypertension related complication (Table 4). 
 
Portal vein thrombosis after surgery 
Five (11%) patients developed de novo portal vein thrombosis (PVT), 28 (range 1-45) days 
after surgical intervention (Supplementary Table 7). Interestingly, 3 out of these 5 surgeries 
were splenectomies, whereas 2 had other surgical interventions. PVT occurred in 3 out of 
the 6 patients (50%) who had splenectomy vs. 2 out of the 39 (5%) who had another surgical 
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out of the 3 patients received anticoagulation, and complete recanalization was observed 
after 4 and 5.5 months, respectively. The third patient did not receive anticoagulation, since 
a TIPSS was inserted; complete recanalization was observed after 8 months.  
 
Death after surgery 
Thirteen (29%) patients were admitted in intensive care unit after surgery, with a median 
(IQR) length of stay in intensive care unit of 4 (2-7) days. Median (IQR) overall length of 
hospital stay was 10 (4-28) days. Four patients died within 6 months after surgery. Their 
characteristics are presented in Table 5. None of the patients underwent liver transplantation 
within the observation period.  
As shown in Table 4, age-adjusted Charlson comorbidity index and serum creatinine level 
were associated with death within 6 months after surgery. Patients with age-adjusted 
Charlson comorbidity index 6 before surgery had a 6-month cumulative risk of death of 
27% vs. 0% for patients with an index below this threshold (p=0.002). We have previously 
reported that serum creatinine level higher than 100 µmol/L is associated with a poor 
outcome after TIPSS in patients with INCPH (25). Using this threshold here, we observed 
that patients with serum creatinine 100 mol/L had a 6-month cumulative risk of death of 
33% vs. 0% for patients with serum creatinine below this threshold (Figure 1).  
We compared 6-month cumulative risk of death after abdominal surgery of patients with 
INCPH with that of patients with cirrhosis matched according to the presence of ascites at 
surgery. One patient with INCPH could not be matched according to the presence of ascites, 
explaining why 43 patients with INCPH were compared with 86 patients with cirrhosis. 
Characteristics of the 86 patients with cirrhosis are shown in Supplementary Table 3. As 
shown in Figure 1B, 6-month cumulative risk of death was similar between the two groups.  
In addition, in order to evaluate the impact of abdominal surgery on overall outcome of 
patients with INCPH, we compared 3-year liver transplantation-free survival of patients with 
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from the present study) with that of patients with INCPH but without abdominal surgery (n= 
82). As shown in Figure 1C, 3-year transplant-free survival was similar between the two 
groups. 
 
Overall post-operative unfavorable outcome  
Overall post-operative outcome was unfavorable in 22 (50%) patients. History of ascites was 
associated with an unfavorable outcome (Table 4). As extra-hepatic conditions related with 
INCPH and serum creatinine levels fell short of statistical significance and as we have 
previously reported that these features are associated with a poor outcome after TIPSS in 
patients with INCPH (25), we classified patients according to these items and to history of 
ascites at surgery. As shown in Figure 2, 5% of the patients with neither extra-hepatic 
condition associated with INCPH nor history of ascites at surgery nor serum creatinine ≥100 
µmol/L had an unfavorable outcome. Only one patient without these criteria had an 
unfavorable outcome; this patient had post-operative bleeding after cholecystectomy, 
requiring reintervention under local anesthesia. By contrast, 64% of the patients with ≥2 
features had an unfavorable outcome.  
 
Influence of portal decompression on post-operative outcome 
As shown in Figure 3, 11 patients had portal decompression prior to, or at the time of, 
surgery. In 1 of these patients, portosystemic shunt was the indication for surgery, with 
concomitant splenectomy (Table 2 and Figure 3). In the 10 remaining patients, median time 
between portal decompression and surgical intervention was 4.0 (0.3-44.6) months. 
In order to assess the effect of portal decompression on the outcome after surgery, we 
compared the outcome of the 10 patients who had either TIPSS or portosystemic shunt 
before surgery, to the 33 patients who did not (Supplementary Table 8). Except for beta-
blockers, baseline characteristics did not differ between the two groups. Post-operative 
outcomes did not differ between patients with previous TIPSS or portosystemic shunt and 
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patient had a grade 3 complication within one month after surgery (leakage), and 3 had at 
least one portal hypertension related complications within 3 months after surgery (1 
decompensation of ascites, 1 decompensation of ascites and encephalopathy and 1 acute 
kidney injury). When included in the univariate Cox regression analysis, portal 
decompression was not associated with neither portal hypertension related complications 
(HR (95% CI) 0.746 (0.212-2.618), p=0.647) or death within 6 months after surgery (HR 
(95% CI) 1.153 (0.120-11.088), p=0.902). Furthermore, portal decompression was not 




This study focusing on the outcome of patients with INCPH undergoing abdominal surgery 
shows that 6-month mortality after surgery was 9%, affecting patients with comorbidities 
and/or serum creatinine level  100 µmol/L. Patients without extra-hepatic conditions related 
with INCPH, without increased serum creatinine and without a history of ascites at surgery 
had a favorable post-operative outcome. Although this study gathered the largest number of 
patients with INCPH undergoing abdominal surgery reported at present, interpretation of the 
results should take into account that number of patients included remained limited, that the 
study was retrospective, and that various surgical interventions were performed. Given the 
rarity of the disease, conducting a prospective study seems however not realistic.  
The main information derived from this study is that mortality of patients with INCPH 
undergoing abdominal surgery is higher than that reported in the general population. We 
observed a 6-month mortality rate of 9% (95% CI 1-17%) in patients with INCPH, while in 
the general population, in-hospital or 1-month mortality after abdominal surgery ranges from 
3 % (95% CI 0.4-7%) to 12% (95% CI 7-18 %) (35–37). We observed that 6-month mortality 
rate of patients with INCPH did not differ from that of patients with cirrhosis, matched for 
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be noted that mortality of patients with cirrhosis in this cohort was lower than previously 
reported (7,10,31–33). Indeed, in patients with cirrhosis, reported mortality after surgery 
ranges from 7 % (95% CI 2-12%) to 30 % (95% CI 15-44%) (7,8,31,33) at 1 month, is of 
30% (24-36) at 3 months and 54% (47-61) at 1 year (32). This lower mortality observed here 
in patients with cirrhosis may be related to a better selection of candidates for abdominal 
surgery, and to the fact that these procedures were performed in tertiary centers. This 
outcome of patients with INCPH after surgery echoes the overall survival of patients with 
INCPH outside the surgical setting, known to be intermediate between those of the general 
population and of patients with cirrhosis (23). In the present study, comorbidities were the 
main drivers of postoperative mortality, as death within six months after surgery was 
restricted to patients with age-adjusted Charlson comorbidity index ≥ 6 or with serum 
creatinine 100 mol/L before surgery. This finding is in line with the natural history of 
INCPH, where half the mortality is accounted for by extrahepatic comorbidities (22–24), as 
well as with the outcome after TIPSS placement where mortality is associated with serum 
creatinine and the presence of extra-hepatic conditions associated with INCPH (25). 
Interestingly, transplant-free survival after INCPH diagnosis was similar in patients who did 
and did not undergo abdominal surgery during follow-up, suggesting that, in selected 
patients managed in expert centers, surgery does not have a deleterious impact on the 
natural history of INCPH. We did not find any association between the type of intervention 
and post-operative outcomes, but cannot rule out a lack of power due to the limited sample 
size.   
The second major finding of the present study was that portal hypertension related 
complications, especially ascites, were the most frequent, occurring within 3 months after 
surgery in 36% and 26% of the patients, respectively. Portal hypertension related 
complications increased the length of hospital stay, and 3/16 (19%) required a TIPSS after 
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patients. These results suggest that portal hypertension per se, should not be regarded as a 
definite contra-indication for abdominal surgery in patients with INCPH.  
De novo PVT occurred in 5 (11%) patients after surgery. Interestingly, PVT following 
splenectomy was 10-fold more frequent than following other surgeries. Reported rates of 
PVT following splenectomy range between 17% (95% CI 13-21%) and 36% (95% CI 17-
55%) in patients with cirrhosis (38,39), and are of 54% (95% CI 46-61%) in patients with 
benign hematologic disorders (40). In the present study, the incidence of PVT was similar to 
that of non-cirrhotic patients, since PVT was observed in 50% (95% CI 9-90%) of the 
patients with INCPH and splenectomy. Four cases of PVT were diagnosed within one month 
after surgery. Recanalization occurred in 60% of the patients. These findings suggest that 
routine ultrasound examination at 1 week, 1 month and 3 months after surgery would allow 
an early detection of PVT, especially after splenectomy.  
Infections within 1 month after surgery were common, being observed in 34% of the 
patients. This figure is in the same range as estimates of post-operative infections after 
abdominal surgery in patients with cirrhosis and higher than in the general population [29% 
(95% CI 21-36%) and 13% (95% CI 12-14%), respectively, p<0.001] (41). In cirrhosis, the 
risk of infection is likely related to altered innate and adaptive immunity and to increased 
bacterial translocation (42). In patients with INCPH, susceptibility to infection may be related 
to portal hypertension but also to extrahepatic conditions associated with INCPH, namely 
immunological disorders and HIV infection. Bleeding occurred within 1 month in 10 (22%) 
patients and was associated with administration of anticoagulant or antiplatelet agents. This 
high incidence is reminiscent of the frequent bleeding episodes reported in patients with 
Budd-Chiari syndrome undergoing invasive procedures while receiving anticoagulation 
therapy (43).  
In the present study, we identified a group of patients having an unfavorable outcome, 
namely those with extra-hepatic condition associated with INCPH, elevated serum creatinine 
and/or significant ascites before surgery. By contrast, only 5% of the patients with neither 
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ascites before surgery had an unfavorable outcome. These simple features could be helpful 
in making a decision for abdominal surgery with due information of the patient on the risks of 
the intervention. Due to the retrospective and uncontrolled design of the study, we could not 
evaluate the survival benefit of surgery (vs. no intervention), taking into account the 
indication of surgery, the severity of INCPH and extrahepatic comorbidities.  
In patients with cirrhosis, the experience of pre-emptive TIPSS placement before surgery is 
limited to small, retrospective studies (12–17). A limited number of studies compared 
patients with cirrhosis with preserved or moderately impaired liver function who had pre-
operative TIPSS, to patients who underwent elective surgery without preoperative TIPSS. 
Outcome after surgery was similar between patients who had or not a preoperative TIPSS 
(15,17). In the present study, portal decompression was not associated with post-operative 
outcome after surgery. However, present findings are insufficient to draw any firm conclusion 
for or against preemptive portal decompression before surgery in patients with INCPH. 
Indeed, TIPSS was placed as a preparation for surgery in only 4 patients; in the 5 remaining 
patients, TIPSS had been previously inserted for other reasons, with sometimes a broad 
interval of time between TIPSS insertion and surgery. Larger dedicated studies are thus 
needed to address this important question.  
In conclusion, in this study, we observed that patients with INCPH were at high risk of major 
surgical and portal hypertension related complications when they harbored extrahepatic 
conditions related to INCPH, and/or increased serum creatinine and/or a history of ascites. 
Comorbidities and higher serum creatinine were significantly associated with 6-month 
mortality. Further studies are needed to evaluate the impact of each type of surgery on the 
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Figures’ legends. 
Figure 1.  
Figure 1A: Cumulative incidence of death at 6 months after abdominal surgery, 
according to serum creatinine before surgery 
Figure 1B: Cumulative incidence of death at 6 months after abdominal surgery in 44 
patients with INCPH and in 86 patients with cirrhosis matched for ascites at surgery 
Figure 1C: Transplant-free survival, from date of diagnosis of INCPH, in patients 
undergoing or not abdominal surgery during follow-up. Each red arrows indicates an 
abdominal surgery. For 8/29 patients, INCPH was diagnosed at surgery (red star). 
Abbreviation: INCPH, idiopathic noncirrhotic portal hypertension 
 
Figure 2. Proportion of the patients having an unfavorable outcome after surgery 
according to the presence of extra-hepatic conditions associated with INCPH serum 
creatinine ≥100 µmol/L and/or history of ascites at surgery. 
An unfavorable outcome was defined as any of post-operative complication grade 3 within 
one month after surgery, portal-hypertension related complications within 3 months after 
surgery or death within 6 months after surgery. 
Eleven patients had neither extra-hepatic condition associated with INCPH nor serum 
creatinine ≥100 µmol/ nor history of ascites at surgery; 17 patients one out of the 3 features 
among extra-hepatic condition associated with INCPH, serum creatinine ≥100 µmol/ or 
history of ascites at surgery; 16 patients at least 2 of the 3 features.  
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Table 1. Characteristics of the 44 patients at surgery 
 
Characteristics  Patients with 
available data 
Number (percentage) or 
median (interquartile 
range) 
Clinical features   
Male gender 44 30 (68) 
Age, years 44 53 (37-65) 
Age adjusted - Charlson comorbidity 
index 
44 4 (3-6) 
ASA score 44 3 (2-3) 
At least one extra-hepatic condition 
associated with INCPH 
44 25 (57) 
Immunological disorder  18 (41) 
HIV infection  5 (11) 
Recurrent abdominal infection  5 (11) 
Medication or toxin  5 (11) 
Prothrombotic condition  2 (5) 
Genetic disorder  2 (5) 
At least one other cause of chronic liver 
disease 
44 11 (25) 
Excessive alcohol consumption  2 (4) 
Metabolic syndrome  5 (11) 
Hepatitis C virus infection  4 (9) 
Diabetes mellitus 44 13 (30) 
Ascites 
Absent  
Controlled with diuretics 





History of ascites * 44 16 (36) 
Hepatic encephalopathy 44 0 (0) 
Previous variceal bleeding 43 18 (42) 
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Treatment before surgery   
Anticoagulation therapy 43 16 (36) 
Antiplatelet agents 43 7 (16) 
Diuretic therapy 43 15 (34) 
Beta-blockers 43 18 (41) 
   










Varices needing treatment**  30 (71) 
   
Imaging data   
Portosystemic collaterals at imaging 43 25 (58) 
Spleen size, cm  35 16 (14-20) 
Previous splenectomy 45 3 (7) 
Thrombosis of the portal venous axis  
Partial occlusion 
Complete occlusion 
43 6 (14) 
3 (7) 
3 (7) 
   
Laboratory data   
Hemoglobin, g/dL 42 11.8 (10.0-13.9) 
Leucocyte count, x109/L  41 5.2 (3.4-10.0) 
Platelet count, x109/L 42 87 (67-161) 
INR 42 1.13 (1.02-1.47) 
AST, IU/L  43 32 (25-47) 
ALT, IU/L  42 26 (19-37) 
ALK, IU/L  41 136 (77-251) 
GGT IU/L  42 57 (23-127) 
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Serum creatinine, mol/L 44 79 (61-106) 
Serum albumin, g/L  34 37 (31-41) 
MELD score 39 9 (7-12) 
 
*History of ascites at surgery was defined either as a previous history of ascites that was 
controlled with diuretics at the time of surgery, or clinically detected ascites at surgery.   
** Medium/large esophageal and/or gastric varices or history of variceal bleeding or history 
of endoscopic band ligation and/or glue 
Abbreviations: ASA, American Society of Anesthesiologists; INCPH, idiopathic noncirrhotic 
portal hypertension; HIV, human immunodeficiency virus; AST, Aspartate aminotransferase; 
ALT, alanine aminotransferase; ALK, alkaline phosphatase; GGT, gamma glutamyl 
transpeptidase; IU, international Unit; MELD, Model for End-Stage Liver diseases 
 
 
Table 2. Type and indications for the 45 surgical interventions 
 
Minor surgeries 30 
Open surgeries 18 
Abdominal wall 13 
Hernia repair 10 
Alfapump implantation 1 
Abdominoplasty 1 
Surgical exploration 1 
Cholecystectomy 2 
Retroperitoneum mass excision 1 
Appendicectomy 1 
Cesarean section 1 
  
Laparoscopic surgeries 12 
Abdominal wall 2 
Surgical exploration 1 
Peritoneal catheter placement 1 
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Splenectomy 1 
Colorectal surgery 4 
Ileal resection (Crohn’s disease) 2 
Appendicectomy  2 
Partial liver resection 1 
  
Major surgeries 15 
Urologic or kidney surgery 5 
Renal transplantation 2 
Nephrectomy  2 
Renal carcinoma 1 
Bleeding after renal biopsy 1 
Cystectomy and hysterectomy for urothelial carcinoma 1 
Splenectomy 5 
Splenectomy alone 3 
Splenectomy + caudal pancreatectomy 1 
Splenectomy + porto-caval shunt 1 
Colic resection 2 
Crohn’s disease                 1 
Colorectal cancer                 1 
Gastric and pancreatic surgery 2 
Gastrectomy for gastric neoplasia 1 
Pancreatectomy for neuroendocrine neoplasia 1 
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Table 3. Details on 61 surgical or post-operative complications that occurred in 31 
patients within 1 month after surgery  
 
Type of complication  
Infection 
Lung 




Clostridium difficile infection 
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Liver 

















*All the 7 reported complications were classified grade I according to the Dindo-Clavien 
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Table 4. Univariate Cox regression analysis evaluating pre-specified factors before 
surgery, associated with the occurrence of major endpoints after surgery 
 
 At least one grade 3 or more complication within 1 
month after surgery (n=9) 
 HR 95% CI P value 
Age-adjusted comorbidity index 1.103 0.866 1.404 0.427 
Extra-hepatic condition associated 
with INCPH 
1.387 0.331 5.810 0.654 
History of ascites* 1.340 0.300 5.988 0.702 
Varices needing treatment** 2.056 0.240 17.600 0.511 
Portal vein thrombosis 2.104 0.363 12.196 0.407 
Serum bilirubin 1.012 0.994 1.031 0.189 
Serum creatinine 1.002 0.999 1.006 0.188 
Major surgery  0.556 0.138 2.242 0.409 
Emergency procedure 2.920 0.712 11.981 0.137 
     
 At least one portal hypertension related 
complication£ within 3 months after surgery 
(n=16) 
 HR 95% CI P value 
Age-adjusted comorbidity index 1.074 0.913 1.264 0.390 
Extra-hepatic condition 
associated with INCPH 
3.973 1.129 13.982 0.032 
History of ascites* 3.144 1.162 8.504 0.024 
Varices needing treatment** 0.858 0.298 2.472 0.777 
Portal vein thrombosis 0.750 0.170 3.304 0.704 
Serum bilirubin 0.991 0.972 1.012 0.401 
Serum creatinine 1.002 0.999 1.005 0.112 
Major surgery  0.634 0.236 1.704 0.366 
Emergency procedure 1.676 0.581 4.830 0.339 
     
 Death within 6 months after surgery (n=4) 
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Age-adjusted comorbidity index 1.372 1.040 1.810 0.025 
Extra-hepatic condition associated 
with INCPH 
0.800 0.113 5.679 0.823 
History of ascites* 5.292 0.550 50.919 0.149 
Varices needing treatment** 1.116 0.116 10.728 0.925 
Portal vein thrombosis 0.039 <0.001 6466.507 0.597 
Serum bilirubin 0.797 0.622 1.022 0.074 
Serum creatinine 1.007 1.003 1.012 0.002 
Major surgery  0.487 0.069 3.455 0.471 
Emergency procedure 0.992 0.103 9.540 0.994 
     
     
     
     
     
     
 Unfavorable outcome after surgery$ (n=23) 
 HR 95% CI P value 
Age-adjusted comorbidity index 1.099 0.963 1.254 0.163 
Extra-hepatic condition 
associated with INCPH 
2.410 0.939 6.186 0.067 
History of ascites* 3.892 1.650 9.180 0.002 
Varices needing treatment** 1.007 0.390 2.598 0.989 
Portal vein thrombosis 1.425 0.479 4.237 0.524 
Serum bilirubin 0.999 0.985 1.014 0.901 
Serum creatinine 1.003 1.000 1.005 0.056 
Major surgery  0.851 0.356 2.032 0.716 
Emergency procedure 2.136 0.865 5.276 0.100 
 
*History of ascites at surgery was defined either as a previous history of ascites that was 
controlled with diuretics at the time of surgery, or clinically detected ascites at surgery.   
** Medium/large esophageal and/or gastric varices or history of variceal bleeding or history 
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£Portal hypertension-related complications were defined as any of decompensation ascites, 
hepatic encephalopathy, significant portal hypertension related bleeding, acute kidney injury, 
or spontaneous bacterial peritonitis occurring within 3 months after surgical intervention. 
Decompensation of ascites was defined as follows: (i) in patients without ascites, onset of 
clinically detectable ascites, confirmed by ultrasonography; (ii) in patients with previous 
ascites not requiring paracentesis, ascites requiring two or more paracentesis within 3 
months following surgery, or requiring a TIPSS. 
$An unfavorable outcome after surgery was defined as either post-operative complication 
grade 3 within one month after surgery, or portal-hypertension related complications within 
3 months after surgery or death within 6 months after surgery. 
 
Abbreviations: HR, Hazard ratio; CI, confidence interval, INCPH, idiopathic noncirrhotic 
portal hypertension 
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Table 5. Characteristics of the 4 patients who died within 6 months after surgery 
 
 PATIENT 7 PATIENT 8 PATIENT 20 PATIENT 41 
Patient’s features at surgery 
Age, years 73 65 51 66 
Gender Male Male Male Male 
Age-adjusted Charlson 
comorbidity index 
8 6 9 8 
ASA score 3 3 3 4 
Extra-hepatic condition 












History of variceal bleeding No No Yes Yes 
Esophageal varices Medium-size Absence Medium-size Medium-size 
Portal vein thrombosis  No No No No 
Platelet count, x10
9
/l 99 273 144 52 
INR 1 1 0.94 1.16 
Serum bilirubin, mol/l 16 6 8 8 
Serum creatinine, mol/l 533 300 552 143 
MELD  14 12 14 9 
     
                                                                             Surgery 
TIPSS performed before 
surgery 
No Yes No No 















     
                                                                         Post-operative outcome 
Occurrence of portal-
hypertension related 


































Duration between surgery 
and death 
5.7 months 2.2 months 4.3 months 3.8 months 
Cause of death Variceal bleeding Cardiac arrest Pneumonia Septic shock 
 
Abbreviations: ASA, American Society of Anesthesiologists; INCPH, idiopathic noncirrhotic 
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